Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...

Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.

Yuhan sealed a $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the ...

Expansion and export plan a step towards getting the US Food and Drug Administration (FDA) certification, says chief ...

South Korean pharmaceutical giant Yuhan announced Friday it has terminated its collaboration with Janssen Biotech on the ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

In March, Gilead Sciences reported positive results for its TROPiCS-02 study of Trodelvy, but the guarded tone of the announcement led to speculation that the data was not as strong as hoped.

Now, Gilead Sciences and MSD have data on a new combination that provides viral suppression with an oral dose given once a week. The phase 2 study – reported at the Conference on Retroviruses ...

Two specialists are impressed by the preliminary findings of a randomized trial in newly diagnosed patients, but another is ...